Vericel Corp (VCEL) Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Vericel Corporation is a commercial-stage biopharmaceutical company focused on advanced therapies for sports medicine and severe burn care. Its primary products are MACI (cartilage repair), Epicel (skin replacement for burns), and NexoBrid (eschar removal for burns). The company operates as a single reportable segment and is currently transitioning MACI manufacturing to a new facility in Burlington, Massachusetts, which received FDA approval in March 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $68.4 million | $52.6 million |
| Gross Profit | $49.3 million | $36.3 million |
| Gross Margin | 72.0% | 69.0% |
| Net Loss | $(6.3) million | $(11.2) million |
| Diluted EPS | $(0.12) | $(0.23) |
| Operating Cash Flow | $16.4 million | $6.6 million |
| Cash & Investments | $210.6 million | $118.4 million |
| Debt | $0 (No borrowings) | $0 |
Note: Cash & Investments includes $109.3 million in cash/cash equivalents and $101.3 million in short-term and long-term investments.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 30.1% year-over-year, driven by a 21.8% increase in MACI revenue and a 119.3% surge in Epicel revenue. NexoBrid revenue declined 14.6%.
- Profitability Improvement: Net loss narrowed by 44.0% to $6.3 million, primarily due to revenue growth outpacing operating expense increases.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 17.8% to $49.2 million, attributed to sales force expansion and costs associated with the new Burlington facility. R&D expenses increased 11.6% to $8.1 million due to higher headcount.
- Cash Flow: Operating cash flow more than doubled to $16.4 million, supported by strong collections (decrease in accounts receivable) and non-cash stock-based compensation of $11.3 million.
Outlook, Commentary, and Risks
- Strategic Developments: On March 31, 2026, Vericel entered a ten-year agreement with BARDA valued at up to $196.9 million for NexoBrid procurement, inventory management, and potential U.S. manufacturing facility development. The base period includes $34.9 million in funding.
- Manufacturing: The company has begun transitioning MACI production to the Burlington facility following FDA approval. This facility is intended to eventually serve as the primary site for both MACI and Epicel.
- Pipeline: The company initiated the MASCOT clinical trial for MACI use in ankle cartilage defects (OLT) in Q4 2025. It is also pursuing regulatory approval for MACI in the United Kingdom, with commercialization anticipated in 2027.
- Liquidity: Management expects current cash, investments, and borrowing capacity to support operations for at least 12 months. The company maintains a $150 million revolving credit facility with no outstanding borrowings.
- Risks: Key risks include supply chain disruptions (NexoBrid is manufactured in Israel with raw materials from Taiwan), reliance on third-party payers for reimbursement, and the success of clinical trials for label expansions.
Investor Verification Checklist
- BARDA Agreement Terms: Verify the specific milestones and funding release conditions within the new $196.9 million BARDA contract.
- MACI Arthro Adoption: Monitor the rate of surgeon adoption for the arthroscopic delivery method and its impact on MACI volume growth.
- Epicel Volatility: Assess the sustainability of the 119% revenue increase in Epicel, given the inherent variability of burn care demand.
- Manufacturing Transition: Confirm the timeline and potential operational disruptions associated with moving MACI production to the Burlington facility.
- Reimbursement Rates: Review trends in third-party payer reimbursement rates and denial rates for MACI implants, which significantly impact net revenue.